parp inhibitors for metastatic hormone sensitive prostate cancer
Published 1 year ago • 335 plays • Length 3:47Download video MP4
Download video MP3
Similar videos
-
2:30
parp inhibitors plus novel endocrine agents for patients with metastatic prostate cancer
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer
-
1:01
choosing the correct parp inhibitor for prostate cancer
-
2:09
current perspectives from clinical trials using parp inhibitors for prostate cancer
-
1:31
tackling disease progression whilst using parp inhibitors for prostate cancer
-
0:31
which mutations benefit most from parp inhibitors in prostate cancer?
-
0:57
when is the optimal time to use parp inhibitors in prostate cancer patients?
-
4:02
the emerging role of parp inhibitors in prostate cancer
-
1:21
combining a parp and pd-l1 inhibitor to treat prostate cancer
-
3:56
parp inhibitors: activity in brca1 versus brca2 altered mcrpc
-
1:53
the evolving role of parp inhibitors in mcrpc
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
3:13
impact of specific mutations on parp inhibition in prostate cancer
-
1:34
combination therapies for the treatment of prostate cancer
-
4:55
parp inhibitors in castrate-resistant prostate cancer
-
1:27:23
the role of parp inhibitors in advanced prostate cancer (2023)
-
1:15
exciting times for hormone-sensitive prostate cancer treatment
-
12:50
parp inhibitors for metastatic castration-resistant prostate cancer